Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific microbial members of the microbiota is challenging, because clinically detectable inflammation and its treatment can alter the microbiota's composition. Immunologic checkpoint blockade with ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a prospective study of patients with metastatic melanoma undergoing ipilimumab treatment and correlate the pre-inflammation faecal microbiota and microbiome composition with subsequent colitis development. We demonstrate that increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved in polyamine transport and B vitamin biosynthesis is associated with an increased risk of colitis. Identification of these biomarkers may enable interventions to reduce the risk of inflammatory complications following cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In parallel to microbial therapeutics, microbial signatures are being evaluated as a novel class of biomarkers, applied for stratification of efficacy and safety in clinical trials across multiple indications (Ananthakrishnan et al., 2017; Dubin et al., 2016).”
From Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers (2021) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The capacity of the microbiome to generate polyamines has also been associated with reduced toxicity of antibody to CTLA-4 in melanoma patients (22).”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“differences may be related to several different factors – including differences in techniques used to analyze samples and reference databases used for analysis – which varied widely across the studies”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CTLA-4 blockade (alone or in combination with anti-PD-1/PD-L1) produces toxicities in a dose-dependent fashion.22,23”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, there is evidence that the microbiome is associated with development of immune-related adverse events (irAEs) following ICB7–9.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [8]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationUCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Cited by
Items 501–600 of 991
Acute Kidney Injury Induced by Immune Checkpoint Inhibitors
Tian, R., Liang, J., Li, R., & Zhou, X. (2022) · Kidney Diseases · doi:10.1159/000520798 · Cited by 25
Cao, T., Zhou, X., Wu, X., & Zou, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1207544 · Cited by 27
Mechanisms and biomarkers of immune-related adverse events in gastric cancer
Ding, P., Liu, P., Meng, L., & Zhao, Q. (2023) · European journal of medical research · doi:10.1186/s40001-023-01365-3 · Cited by 25
Microbiome and cancer immunotherapy
Chilakapati, S. R., Ricciuti, J., & Zsíros, E. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.02.007 · Cited by 23
Park, R., Umar, S., & Kasi, A. (2020) · Current Colorectal Cancer Reports · doi:10.1007/s11888-020-00456-1 · Cited by 28
Han, Y., Wang, J., & Xu, B. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103376 · Cited by 24
Najmi, M., Tran, T., Witt, R. G., & Nelson, K. C. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00810-1 · Cited by 21
The Role of Gut Microbiota in Modulating Cancer Therapy Efficacy
Madkour, M. A., Altaf, R. A., Sayed, Z. S., Yasen, N. S., Elbary, H. A., Elsayed, R. A., Mohamed, E. N., Toema, M., Wadan, A.-H. S., Nafady, M. H., et al. (2024) · Advanced Gut & Microbiome Research · doi:10.1155/2024/9919868 · Cited by 25
Harnessing the microbiome for cancer therapy
Hajjar, R., Mars, R. A. T., & Kashyap, P. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01268-6 · Cited by 34
Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy
Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 22
Wang, J., Yang, H.-R., Wang, D.-J., & Wang, X.-X. (2020) · Oncology Letters · doi:10.3892/ol.2020.12205 · Cited by 23
“Taken together, these findings indicated that the effects and toxicities associated with anti‐CTLA‐4 treatment may be influenced by the profile and concentration of intestinal bacteria (21,22).”
BackgroundConnecting the dots: Targeting the microbiome in drug toxicity
Luo, Y., & Zhou, T. (2021) · Medicinal Research Reviews · doi:10.1002/med.21805 · Cited by 21
“A prospective study involving 36 patients with metastatic melanoma under ipilimumab treatment suggests a higher abundance of the Bacteroidetes phylum is correlated with resistance to ipilimumab‐induced colitis.(174) A similar study involving 26 patients reveals that baseline microbiota enriched with the Firmicutes phy…”
BackgroundTan, B., Chen, M., Guo, Q., Tang, H., Li, Y., Jia, X., Xu, Y., Zhu, L., Wang, M., & Qian, J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13990 · Cited by 22
“Previous studies showed the patients with low Bacteroidetes/Firmicutes ratios were prone to better clinical responses and ICI-related colitis.(8,25) In pancreatic disease, the AIP patients had lower Bacteroides species than CP patients.”
ResultYin, J., Elias, R. M., Peng, L., Levonyak, N. S., Asokan, A., Christie, A. L., Kubiliun, N. M., Brugarolas, J., & Hammers, H. J. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.01.017 · Cited by 24
Miya, T. V., Marima, R. M., Damane, B. P., Ledet, E. M., & Dlamini, Z. (2023) · Cancers · doi:10.3390/cancers15164086 · Cited by 33
“Furthermore, composition of the gut microbiota seems to be linked with increased risk of anti-CTLA-4-stimulated colitis in patients with metastatic melanoma [118,119].”
BackgroundGut microbiome and checkpoint inhibitor colitis
Sehgal, K., & Khanna, S. (2020) · Intestinal Research · doi:10.5217/ir.2020.00116 · Cited by 21
“Polyamines (amines that are exported from cells of bacteria via specific transport systems) are believed to maintain the colonic epithelial barrier by encouraging proliferation and the enzymes involved in the synthesis of these polyamines are lower in patients with colitis.(13) Subsequent data gathered from various ot…”
BackgroundResultInfluentialLauwyck, J., Beckwée, A., Santens, A., Schwarze, J. K., Awada, G., Vandersleyen, V., Aspeslagh, S., & Neyns, B. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000748 · Cited by 27
Role of the gut microbiome in Alzheimer’s disease
Chok, K. C., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0122 · Cited by 23
The cure from within? a review of the microbiome and diet in melanoma
Kumar, P. R., Brazel, D., DeRogatis, J. M., Goldstein, J. B., Whiteson, K., Chow, W. A., Tinoco, R., & Moyers, J. T. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10029-3 · Cited by 25
“In a separate prospective study of 34 metastatic melanoma, patients who developed ipilimumabassociated colitis (n = 10) had decreased Bacteroidetes in pre-treatment fecal samples [81].”
BackgroundWu, L., Yang, P., Luo, L., Zhu, W., Hong, Y., Tong, C., & Peñuelas, J. (2022) · Geoderma · doi:10.1016/j.geoderma.2022.115907 · Cited by 30
Inoue, Y., Inui, N., Karayama, M., Asada, K., Matsuura, S., Ikeda, M., Uto, T., Fujii, M., Hashimoto, D., Matsui, T., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04193-w · Cited by 20
GAUDIO, A. D., Vincenzo, F. D., Petito, V., Giustiniani, M. C., Gasbarrini, A., Scaldaferri, F., & Lopetuso, L. R. (2023) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad229 · Cited by 24
“56 In contrast, increased Bacteroides fragilis , due to its anti-inflammatory activity, is considered a protective factor against ICI colitis.”
BackgroundLessomo, F. Y. N., Mandizadza, O. O., Mukuka, C., & Wang, Z. (2023) · European journal of medical research · doi:10.1186/s40001-023-01464-1 · Cited by 24
Riveiro‐Barciela, M., Carballal, S., Díaz‐González, Á., Mañosa, M., Gallego-Plazas, J., Cubiella, J., Jiménez‐Fonseca, P., Varela, M., Menchen, L. A., Sangro, B., et al. (2024) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2023.10.009 · Cited by 25
Microbiote intestinal et réponses aux thérapies anti-tumorales
Vétizou, M., Daillère, R., & Zitvogel, L. (2016) · médecine/sciences · doi:10.1051/medsci/20163211013 · Cited by 24
Davar, D., & Bahary, N. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0547-9 · Cited by 21
Lower risk of severe checkpoint inhibitor toxicity in more advanced disease
Verheijden, R. J., May, A. M., Blank, C. U., van der Veldt, A. A. M., Boers‐Sonderen, M. J., Aarts, M. J. B., van den Berkmortel, F. W. P. J., van den Eertwegh, A. J. M., de Groot, J. W. B., van der Hoeven, J. J. M., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000945 · Cited by 22
Zhang, S., Zhou, Z., Wang, L., Li, M., Zhang, F., & Zeng, X. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320976996 · Cited by 22
The effect of patient sex on the efficacy and safety of anticancer immunotherapy
Pala, L., & Conforti, F. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1939672 · Cited by 20
“before the development of colitis, thus identifying a specific microbiota-composition, belonging to Bacteroidetes phylum, that is protects from the occurrence of intestinal inflammation [75].”
BackgroundSwami, U., Zakharia, Y., & Zhang, J. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000232 · Cited by 20
Zhang, R., Deng, Q., Jiang, Y., Zhu, H., Wang, J., & Zhao, M. (2019) · Oncology Reports · doi:10.3892/or.2019.7096 · Cited by 22
Khoury, Z. H., Hausner, P. F., Idzik-Starr, C. L., Frykenberg, M. R. A., Brooks, J. K., Dyalram, D., Basile, J. R., & Younis, R. H. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000282 · Cited by 19
The Implication of Gastric Microbiome in the Treatment of Gastric Cancer
Pappas‐Gogos, G., Tepelenis, K., Fousekis, F., Katsanos, K. H., Pitiakoudis, M. S., & Vlachos, K. (2022) · Cancers · doi:10.3390/cancers14082039 · Cited by 23
Vaziri, H., Turshudzhyan, A., & Vecchio, E. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001705 · Cited by 20
Pianko, M. J., & Golob, J. L. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10033-7 · Cited by 23
“In addition to anti-tumor responses, microbial dysbiosis has also been associated with immune checkpoint inhibitor-related colitis [33].”
BackgroundLes, Í., Pérez-Francisco, I., Cabero, M., Sánchez, C., Hidalgo, M., Teijeira, L., Arrazubi, V., Domínguez, S., Anaut, P., Eguiluz, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894550 · Cited by 20
Gut microbiota – a double-edged sword in cancer immunotherapy
Andrews, M. C., & Vasanthakumar, A. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.08.003 · Cited by 20
Wang, S., Peng, D., Zhu, H. S., Min, W., Xue, M., Wu, R., Shao, Y., Pan, L., & Zhu, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1053370 · Cited by 21
Gut microbiota: a potential target for improved cancer therapy
Zhao, M., Jiang, G., Zhou, H., Li, J., Xiang, W., Li, S., Wang, H., & Zhou, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04546-5 · Cited by 20
“In an analysis of gut microbes from 34 patients with metastatic melanoma treated with anti-CTLA-4 antibodies, an increase in the Bacillus phylum was found to be associated with the incidence of immune-associated colitis (Dubin et al. 2016).”
BackgroundThe role of extratumoral and intratumoral microorganisms in cancer immunotherapy
Du, Y., Liu, L., Ma, W., Yan, W., Mao, W., Du, Y., Cui, K., Pu, Y., Li, Z., Sansonetti, P. J., et al. (2023) · The Innovation Life · doi:10.59717/j.xinn-life.2023.100016 · Cited by 21
Roque, K., Ruiz, R., Mas, L. A., Pozza, D. H., Vancini, M., Silva, J. A., & de Mello, R. A. (2023) · Cancers · doi:10.3390/cancers15184547 · Cited by 20
“This discrepancy underscores the potential redundancy of the PD-1 pathway in maintaining immune homeostasis within the gut [78].”
BackgroundMicrobiota: A key factor affecting and regulating the efficacy of immunotherapy
Jiang, Y., Jia, D., Sun, Y., Ding, N., & Wang, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1508 · Cited by 22
Lo, J. W., Schroeder, J.-H., Beattie, G., Roberts, L. B., Cozzetto, D., Omer, O., Ross, E. M., Heuts, F. W. H., Jowett, G. M., Read, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51719-6 · Cited by 27
Expert opinion on immunotherapy induced diabetes
Smati, S., Buffier, P., Bouillet, B., Archambeaud, F., Vergès, B. L., & Cariou, B. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.006 · Cited by 20
CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
Sacchetti, B., Botticelli, A., Pierelli, L., Nuti, M., & Alimandi, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081903 · Cited by 20
“CAR-T cells have been engineering to secrete and deliver PD-1, CTLA-4 or PD-L1 antibodies at the tumor site [94–96].”
Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis
Abu‐Sbeih, H., & Wang, Y. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06103-x · Cited by 20
“[11] studied 34 patients with advanced melanoma and reported that the prevalence of Bacteroidetes phylum was associated with resistance to IEC development, attributing this observation to an increase in T-reg cells.”
BackgroundInfluentialUncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review
Halsey, T. M., Ologun, G. O., Wargo, J. A., & Jenq, R. R. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.05.002 · Cited by 19
“They found that the presence of Bacteroides and select metabolic pathway regulation were associated with a reduced risk for colitis (20).”
BackgroundLipopeptide(s) associated with human microbiome as potent cancer drug
Chauhan, V., & Kanwar, S. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.012 · Cited by 19
González‐Cao, M., Boada, A., Teixidó, C., Fernández‐Figueras, M. T., Mayo, C., Tresserra, F., Bustamante, J., Viteri, S., Puertas, E., Santarpía, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10651 · Cited by 18
“The resident microbiota contain thousands of different bacteria that play an important role in lymphocyte education, with possible value as predictive markers of response [29] and toxicity to ipilimumab [30].”
BackgroundBiomarkers for Checkpoint Inhibition
Weber, J. S. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175463 · Cited by 19
Ngamphaiboon, N., Ithimakin, S., Siripoon, T., Sintawichai, N., & Sriuranpong, V. (2021) · BMC Cancer · doi:10.1186/s12885-021-09003-z · Cited by 19
Leigh, S., Lynch, C. M. K., Bird, B., Griffin, B. T., Cryan, J. F., & Clarke, G. A. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2043849 · Cited by 19
Zhang, H., Lang, X., Li, X., Chen, G., & Wang, C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272310 · Cited by 23
“Cellulolytic bacteria are an important group of bacteria that degrade cellulose in the rumen and play a key role in the production of VFA [44, 45].”
BackgroundDynamic distribution of gut microbiota in cattle at different breeds and health states
Wang, L., Wu, D., Zhang, Y., Li, K., Wang, M., & Ma, J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1113730 · Cited by 18
“Similarly, in Teresa Tavella’s research, Rikenellaceae could significantly reduce visceral adipose tissue and help maintain a healthier metabolic profile, which proved that adequate Rikenellaceae could improve the body’s health and metabolism (Backhed et al., 2015; Dubin et al., 2016).”
Immune‐related adverse events of antibody‐based biological medicines in cancer therapy
Rajagopal, D., MacLeod, E., Corogeanu, D., & Vessillier, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18470 · Cited by 22
“54,55 Efforts on standardization for harmonized and detailed profiling of the gut and tumour microbiome signatures will support the comprehensive understanding of cancer immunotherapy responses and associated toxicities and enable integration of the microbiome-based therapies as an adjunct for…”
BackgroundThe gut microbiome modulate response to immunotherapy in cancer
Jiang, S., Kang, Z., Chen, Y., & Fang, J. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2634-7 · Cited by 22
“In 2016, Dubin et al. (2016) first found an association between gut microbiota and ICIs toxicity in a prospective study.”
Cascade of immunologic adverse events related to pembrolizumab treatment
Dhenin, A., Samartzi, V., Lejeune, S., & Seront, E. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-229149 · Cited by 19
Watson, G. A., Doi, J., Hansen, A. R., & Spreafico, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14355 · Cited by 20
Impact of the ileal microbiota on colon cancer
Roberti, M. P., Rauber, C., Kroemer, G., & Zitvogel, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.016 · Cited by 18
Wang, X., & Jing, J. (2025) · MedComm · doi:10.1002/mco2.70346 · Cited by 27
“…hormone [438, 439], antibodies (such as antithyroglobulin antibodies) [438], cytokines (e.g., IFN-γ [440], CXCL9/10/11 [441]), tumor tissue markers [442], the microbiome [443, 444], and even genetic characteristics [445, 446] are all associated with the occurrence of adverse events.”
Intestinal Microbiota and Host Cooperate for Adaptation as a Hologenome
Zhou, H., Yang, L., Ding, J., Dai, R., He, C., Xu, K., Luo, L., Xiao, L., Zheng, Y., Han, C., et al. (2022) · mSystems · doi:10.1128/msystems.01261-21 · Cited by 19
Sanchez, K. G., Page, D. B., & Urba, W. J. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.009 · Cited by 21
Deng, R., Zhang, H., Li, Y., & Shi, Y. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000442 · Cited by 24
Sun, P., Wang, M., Zheng, W., Li, S., Zhu, X., Chai, X., & Zhao, S. (2023) · Stress Biology · doi:10.1007/s44154-023-00098-x · Cited by 17
Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy
Margolis, N., Markovits, E., & Markel, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.005 · Cited by 20
Manne, A., Mulekar, M. S., Escobar, D. E., Alsayed, A., Sharma, G., Prodduturvar, P., Khushman, M. M., Howard, J. H., Gilbert, R., & Alkharabsheh, O. A. (2021) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4511 · Cited by 20
“Some biomarkers, such as interleukin 17 (IL-17), eosinophil count, combined toxicity scores based on gene expression, autoantibodies, and gut microbiota, have shown correlative results with the incidence of irAE [9-14].”
BackgroundRallis, K. S., Makrakis, D., Ziogas, I. A., & Tsoulfas, G. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i6.448 · Cited by 19
Chye, A., Allen, I., Barnet, M. B., & Burnett, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894015 · Cited by 17
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
Shang, J., Valle, D. M. D., Britton, G. J., Mead, K., Rajpal, U., Chen-Liaw, A., Mogno, I., Li, Z., Menon, R., Gonzalez‐Kozlova, E., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232079 · Cited by 17
Finnicum, C. T., Rahal, Z., Hassane, M., Treekitkarnmongkol, W., Sinjab, A. F., Morris, R., Liu, Y., Tang, E., Viet, S., Petersen, J. L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810930 · Cited by 16
Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
Peng, X., Gong, C., Zhang, W., & Zhou, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1091088 · Cited by 18
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy
Li, Y., Wang, S., Lin, M., Hou, C., Li, C., & Li, G. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0927-0 · Cited by 15
PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
Huang, G., Liu, S., Dong, J., Xi, X., Kong, R., Li, W., & Du, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.974376 · Cited by 16
“Studies have shown that an increased baseline presence of Bacteroidetes species, such as Bacteroidetes, Bacteroidaceae, Rikenellaceae, and Barnesiellaceae, are linked to a reduced risk to colitis (Dubin et al., 2016; Aarnoutse et al., 2019; Som et al., 2019).”
BackgroundPromising and Minimally Invasive Biomarkers: Targeting Melanoma
Spiliopoulou, P., Lopes, C. D. H., & Spreafico, A. (2023) · Cells · doi:10.3390/cells13010019 · Cited by 16
“Species belonging to Bacteroidetes, Clostridia, and Proteobacteria phyla have been linked to increased incidence and severity of immune-related adverse events (irAEs) [214,235,236].”
BackgroundMcKenzie, J., Sneath, E., Trinh, A., Nolan, M. T., & Spain, L. A. (2024) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2024.100704 · Cited by 19
“49,50 The balance of butyrate-producing bacteria (including Faecalibacterium and Agathobacter genera ) appears important and is associated with a lower incidence of irAEs, and lower incidence of colonic irAEs compared to non-colonic irAEs.”
BackgroundThe Current and Future of Biomarkers of Immune Related Adverse Events
Bracamonte‐Baran, W., & Kim, S. T. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.01.004 · Cited by 18
de Jong, C., Peters, B. J. M., & Schramel, F. M. N. H. (2018) · Chemotherapy · doi:10.1159/000494841 · Cited by 16
Ornstein, M. C., Calabrese, C. M., Wood, L. S., Kirchner, E., Profusek, P., Allman, K. D., Martin, A. M., Kontzias, A., Grivas, P. D., Garcia, J. A., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.01.021 · Cited by 15
Prognostic Biomarkers for Melanoma Immunotherapy
Twitty, C., Huppert, L. A., & DAUD, A. I. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0886-z · Cited by 16
Sanz-Segura, P., Cámara, P. G., Bonilla, E. M. F., Arbonés-Mainar, J. M., & Monterde, V. B. (2020) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2020.07.009 · Cited by 18
Li, X., Song, Y., Qin, X., Han, J., & Chang, Y. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.649372 · Cited by 17
“Rikenellaceae, a key intestinal beneficial bacterium, displays multiple physiological functions, such as degrading plant-derived polysaccharides and limit inflammation by stimulating T-regulatory cell differentiation (63, 64).”
BackgroundTian, T., Wang, J., Yin, F., Wu, M., He, W., Wang, X., Zha, Z., & Wang, H. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202102080 · Cited by 19
Lu, C., Zhang, Y., Chen, Z., Zhou, Q., & Wu, Y.-L. L. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836891 · Cited by 18
“02) (38), suggesting that ctDNA dynamics could serve as a reliable molecular biomarker to help determine whether therapeutic interventions should continue after radiological progression to improve patient outcomes.”
BackgroundOey, O., Liu, Y.-Y., Sunjaya, A. F., Simadibrata, D. M., Khattak, M. A., & Gray, E. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i11.929 · Cited by 15
Autoimmune complications of cancer immunotherapy
Dhodapkar, K. M. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.08.004 · Cited by 17
Yue, L., Geng, F., Jin, J., Li, W., Liu, B., Du, M., Gao, X., Lü, J., & Pan, X. (2024) · Biotechnology Journal · doi:10.1002/biot.202400428 · Cited by 14
“Studies have shown that immune checkpoint blockade may alter the immune balance in the gut, leading to a decrease in probiotics such as Akkermansia and Lactobacillus , and an increase in inflammatory microbes such as Bacteroides and Burkholderiales , thereby exacerbating colitis [37, 38].”
Chandrasekaran, P., Krausz, M., Han, Y., Mitsuiki, N., Gabrysch, A., Nöltner, C., Proietti, M., Heller, T., Grou, C., Calderon, V., et al. (2025) · Microbiome · doi:10.1186/s40168-025-02028-7 · Cited by 16
“Other studies have underlined how certain changes in the intestinal microbiota may predispose to colitis associated with anti-CTLA4 and/or anti-PD1 therapy [54–57].”
Santacroce, L., Jirillo, E., Bottalico, L., Topi, S., Passarelli, P. C., Mancini, A., D’Addona, A., García-Godoy, F., Folliero, V., & Colella, M. (2025) · Journal of Oral Microbiology · doi:10.1080/20002297.2025.2569934 · Cited by 16
“Moreover, in melanoma patients treated with ipilimumab, the gut levels of Barnasiellaceae, Bacteroidaceae and Rikenellaceae were associated with resistance to colitis, while intestinal level of Faecalibacterium was related to a more beneficial outcome [81,82].”
Giudice, E., Salutari, V., Ricci, C., Nero, C., Carbone, M. V., Ghizzoni, V., Musacchio, L., Landolfo, C., Perri, M. T., Camarda, F., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103542 · Cited by 16
Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer
Li, N., Wang, G., Hou, X., Tai, R., Huang, S., He, Z., Lei, L., Xu, S., & Yang, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108803 · Cited by 15
Bouferraa, Y., Fares, C., Zerdan, M. B., & Kennedy, L. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119702 · Cited by 15
“It is thought that the Bacteroidetes phylum stimulates Treg cell differentiation, which may play a role in certain patients’ resistance to colitis [60,62,63].”
BackgroundDougan, M. L. (2023) · Immunological Reviews · doi:10.1111/imr.13239 · Cited by 17
Du, E., Jiang, M., Chen, F., Fan, Q., Guo, S., Zhao, N., Jin, F., Guo, W., Huang, S., & Wei, J. (2024) · Poultry Science · doi:10.1016/j.psj.2024.103798 · Cited by 17
“Rikenellaceae are associated with resistance to the development of colitis following cytotoxic T-lymphocyte-associated antigen-4 blockade and can limit in fl ammation by stimulating T-regulatory cell differentiation (Dubin et al., 2016).”
BackgroundZhang, J., Quadri, S. A., Wolfgang, C. L., & Zheng, L. (2018) · Biomedicines · doi:10.3390/biomedicines6030087 · Cited by 18
“A few studies have also suggested the association of members of the gut microbiome with ICI toxicities, but evidence is lacking in the GI setting [21,22].”
BackgroundImmunotherapy induced enterocolitis and gastritis – What to do and when?
Cheung, V., & Brain, O. (2020) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2020.101703 · Cited by 19
GeneMark-HM: improving gene prediction in DNA sequences of human microbiome
Lomsadze, A., Bonny, C., Strozzi, F., & Borodovsky, M. Y. (2021) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqab047 · Cited by 17
Neurological Immunotoxicity from Cancer Treatment
Wesley, S. F., Haggiagi, A. M., Thakur, K. T., & Jager, P. L. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136716 · Cited by 15
Issa, M., Tang, J., Guo, Y., Coss, C. C., Mace, T. A., Bischof, J. J., Phelps, M. A., Presley, C. J., & Owen, D. H. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2094772 · Cited by 15
Solving the puzzle of what makes immunotherapies work
Ma, X., & Chan, T. A.-T. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.011 · Cited by 15
Gut microbes and immunotherapy for non-small cell lung cancer: a systematic review
Jin, Y., Jie, Z., & Fan, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1518474 · Cited by 23
Metadata
- Authors
- Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., Pamer, E. G., & Wolchok, J. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Broad Institute (US)
- Corresponding author
- Pamer, Eric G.
- Wolchok, Jedd D.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-02-02
- Volume
- 7
- Issue
- 1
- Pages
- 10391-10391
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4740747
- OpenAlex
- W2275606382
- Cited by
- 987
- References
- 40
- Citations by year
- 2026: 56 · 2025: 76 · 2024: 83 · 2023: 117 · 2022: 145 · 2021: 128 · 2020: 131 · 2019: 112 · 2018: 71 · 2017: 48 · 2016: 19
- FWCI
- 43.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bristol-Myers Squibb
- Memorial Sloan-Kettering Cancer Center (P30 CA008748)
- Tow Foundation
- National Institutes of Health
- Weill Cornell Medical College
- National Cancer Institute (P30CA008748)
- National Institute of General Medical Sciences (T32GM007739)
- National Institute of Allergy and Infectious Diseases (R01 AI42135, R01AI042135)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- ipilimumab, CTLA-4, metastatic melanoma, gut microbiota, Bacteroidetes, immune-related adverse events, cancer immunotherapy, polyamine transport, B vitamin biosynthesis, biomarkers, inflammatory bowel disease
- MeSH terms
- Gastrointestinal Microbiome, Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Bacteroidaceae, Colitis, Female, Humans, Male, Melanoma, Middle Aged, Prospective Studies, Risk Factors, RNA, Ribosomal, 16S, Skin Neoplasms, Sequence Analysis, RNA, Bacteroidetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.